Dapirolizumab Pegol
Systemic Lupus Erythematosus (SLE)
Phase 3Partnered (UCB)
Key Facts
Indication
Systemic Lupus Erythematosus (SLE)
Phase
Phase 3
Status
Partnered (UCB)
Company
About Silence Therapeutics
Silence Therapeutics is a clinical-stage RNA interference (RNAi) company focused on developing novel siRNA therapeutics. As a pioneer in the field, the company's core technology, mRNAi GOLD™, enables the targeted delivery of siRNAs to hepatocytes in the liver. Its lead asset, zerlasiran (SLN360), is in Phase 2 development for cardiovascular risk reduction, and the company has established significant collaborations with AstraZeneca and Hansoh Pharma to expand its pipeline and validate its platform.
View full company profileTherapeutic Areas
Other Systemic Lupus Erythematosus (SLE) Drugs
| Drug | Company | Phase |
|---|---|---|
| Cenerimod | Idorsia | Phase 3 |
| CLN-978 | Cullinan Therapeutics | Phase 1 |
| Telitacicept | Vor Biopharma | Marketed |
| rese-cel (resecabtagene autoleucel) | Cabaletta Bio | Phase 1/2 |